The Senhance Surgical System is the first and only digital laparoscopic platform designed to maintain laparoscopic minimally invasive surgery standards while providing digital benefits such as haptic feedback, robotic precision, eye-sensing camera control, comfortable ergonomics, advanced instrumentation including 3 mm microlaparoscopic instruments, and reusable standard instruments to help maintain per-procedure costs similar to traditional laparoscopy. TransEnterix also recently launched the first machine vision system in robotic surgery. This first-of-its-kind augmented intelligence capability is powered by the new Intelligent Surgical Unit™ on the Senhance Surgical System.
“Bringing the Senhance Surgical system to the ASC is a major achievement in our vision to be a leading global site for advanced surgical training in minimally invasive technology,” said Prof. Dr. Jaap Bonjer, Professor of Surgery at Amsterdam University Medical Centre and CEO of the ASC. “We believe that the future of surgery will be driven by newer technologies that enable better information guidance in real-time. The Senhance combines machine vision and learning capabilities with precision surgery while also seeking to address high healthcare costs. This technology fits very well with our mission.”
At TransEnterix, Inc., we are digitizing the interface between the surgeon and the patient to improve minimally invasive surgery (MIS) through a new category of care called Digital Laparoscopy. Digitizing the interface enables the use of advanced capabilities like augmented intelligence, connectivity and robotics in laparoscopy, and allows us to address the current clinical, cognitive and economic shortcomings in surgery. The system features the first machine vision system for use in robotic surgery which is powered by the new Intelligent Surgical Unit™ (ISU™) that enables augmented intelligence in surgery. The Senhance® Surgical System brings the benefits of Digital Laparoscopy to patients around the world while staying true to the principles of value-based healthcare. Learn more about Digital Laparoscopy with the Senhance Surgical System here: https://Senhance.com/. Now available for sale in the US, the EU, Japan, Russia, and select other countries. For a complete list of indications for use, please visit: https://www.transenterix.com/indications-for-use/.
About The Amsterdam Skills Centre
The Amsterdam Skills Centre (ASC) offers medical specialists and other health care professionals from all over the world an innovative learning environment with 12 high-tech operating rooms, operating robots, VR-simulators, a learning platform and services to fully digitalize the OR learning experience. The ASC is developing faster, safer and more efficient training modules that enable medical specialists to handle surgical interventions in a short period of time. It is an incubator where people and resources are connected to build a New Way of Learning. Our goal is to build a global scalable, low cost and mobile learning environment which can be implemented on-site, here and in low and middle income countries. The ASC is located on the premises of Amsterdam University Medical Centers.
Learn more at: https://www.asc.amsterdam/
This press release includes statements relating to the Senhance Surgical System and the Company announcing its new training center at the Amsterdam Skills Center in the Netherlands. These statements and other statements regarding our future plans and goals constitute “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether the ASC will be able to meet our commercial needs and whether the Senhance Surgical System technology will be able to meet the mission of the ASC. For a discussion of the risks and uncertainties associated with TransEnterix’s business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 16, 2020 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005617/en/
For TransEnterix, Inc.
Mark Klausner, +1 443-213-0501 email@example.com or Media Contact:
Kristin Schaeffer CG Life +1 814-360-0660 firstname.lastname@example.org
Source: TransEnterix, Inc.